These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 4148588)
1. The doctor and the pharmaceutical industry. Girdwood RH Br J Clin Pract; 1973 Aug; 27(8):279-84. PubMed ID: 4148588 [No Abstract] [Full Text] [Related]
2. Licensing under the Medicines Act and its effect on pharmacy. Fishburn AG R Soc Health J; 1974 Dec; 94(6):271-3, 95. PubMed ID: 4460083 [No Abstract] [Full Text] [Related]
4. Clinical pharmacology in the United Kingdom. Smith RN Clin Pharmacol Ther; 1974 Sep; 16(3):605-15. PubMed ID: 4412474 [No Abstract] [Full Text] [Related]
5. [Pharmaceutical legislation in Great Britain]. GIRARDET E Prod Pharm; 1960 Feb; 15():84-6. PubMed ID: 13828129 [No Abstract] [Full Text] [Related]
6. [Responsibility for drug reactions]. Naess K Nord Med; 1975 Mar; 90(3):65-6. PubMed ID: 1153254 [No Abstract] [Full Text] [Related]
7. [Round table discussion on the Scandinavian drug market: A common pharmacy and therapeutics committee is proposed in view of threats from abroad of lowered standards]. Nord Med; 1974 Jan; 89(1):3-5. PubMed ID: 4856475 [No Abstract] [Full Text] [Related]
8. International Conference on Harmonisation; guidance on Q10 Pharmaceutical Quality System; availability. Notice. Food and Drug Administration, HHS Fed Regist; 2009 Apr; 74(66):15990-1. PubMed ID: 19507321 [TBL] [Abstract][Full Text] [Related]
9. Safety of medicines: the government and the public interest. Cohen RH Proc R Soc Med; 1969 Dec; 62(12):1213-6. PubMed ID: 5391503 [No Abstract] [Full Text] [Related]
10. [The concept of determining national requirements of essential drugs]. Meshkovskiĭ AP Sov Zdravookhr; 1990; (11):62-5. PubMed ID: 2075502 [No Abstract] [Full Text] [Related]
11. Inspections: the international regulatory view--Japan. Kamura S PDA J Pharm Sci Technol; 1994; 48(4):182-3. PubMed ID: 7804816 [No Abstract] [Full Text] [Related]
12. [The EEC creates a European Medical Product Agency]. Johnson K Lakartidningen; 1993 Oct; 90(40):3395. PubMed ID: 8231477 [No Abstract] [Full Text] [Related]
13. [Towards a new drug management]. Hoffmann M; Ahlner J Lakartidningen; 1995 Oct; 92(41):3804, 3807. PubMed ID: 7564634 [No Abstract] [Full Text] [Related]
15. Improving pharmacy and therapeutics committee operations. Cohen MR; Klapp D; Miller KB; Shaffer VL; Slotfeldt M; Miller DE Am J Hosp Pharm; 1984 Sep; 41(9):1767-77. PubMed ID: 6496511 [TBL] [Abstract][Full Text] [Related]
16. [The admission of drugs in the Netherlands]. ten Ham M Ned Tijdschr Geneeskd; 1983 May; 127(22):968-71. PubMed ID: 6866153 [No Abstract] [Full Text] [Related]
17. Symposium on drug safety. The role of regulatory agencies and industry in assessment of the safety of drugs for use in man. The situation in the United Kingdom. Cahal DA Can Med Assoc J; 1968 Feb; 98(6):271-5. PubMed ID: 5636096 [No Abstract] [Full Text] [Related]
18. [The role of the Committee for Medicinal Products for Human Use (CHMP) in the European centralised procedure]. Enzmann H; Schneider C Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):731-9. PubMed ID: 18584106 [TBL] [Abstract][Full Text] [Related]
19. Changes in global pharmaceutical patent strategy due to intergovernmental cooperation. Komatani TS Pharm Pat Anal; 2014 Mar; 3(2):133-6. PubMed ID: 24588589 [No Abstract] [Full Text] [Related]
20. [More stringent requirements in connection with the choice of drugs. Members of the drug committees in Stockholm deliver an annual declaration of challengeability]. Sjöqvist F Lakartidningen; 2001 Feb; 98(6):541-3. PubMed ID: 11475240 [No Abstract] [Full Text] [Related] [Next] [New Search]